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Background: In metastatic breast cancer (MBC), antigen profiles of metastatic tissue and primary tumor differ in up
to 20 % of patients. Reassessment of predictive markers, including human epidermal growth factor receptor 2 (HER2)
expression, might help to optimize MBC treatment. While tissue sampling is invasive and often difficult to repeat, circulating
tumor cell (CTC) analysis requires only a blood sample and might provide an easy-to-repeat, real-time “liquid biopsy”
approach. The present retrospective study was conducted to compare HER2 expression in primary tumors, metastatic
tissue, and circulating tumor cells (CTCs) from MBC patients and to analyze the potential impact of HER2 overexpression
by CTCs on progression-free (PFS) and overall survival (OS) in MBC.
Methods: CTC-positive (five or more CTCs/7.5 mL blood; CellSearch®, Janssen Diagnostics) MBC patients starting a new
line of systemic treatment were eligible for the study. HER2 status of CTCs was determined by immunofluorescence
(CellSearch®). HER2 status of primary (PRIM) and metastatic (MET) tumor tissue was determined by immunohistochemistry.
Data were analyzed using descriptive statistics and Kaplan–Meier plots.
Results: One hundred seven patients (median age (range) 57 (33–81) years) were included. 100/107 (93 %) patients were
followed-up for a median [95 % confidence interval (CI)] of 28.5 [25.1–40.1] months. Of 37/107 (35 %) CTC-HER2-positive
patients only 10 (27 %) were PRIM-HER2-positive. 6/46 (13 %) patients were MET-HER2-positive; only 2/10 (20 %)
CTC-HER2-positive patients were MET-HER2-positive. Overall accuracy between CTC-HER2 expression and PRIM-HER2
and MET-HER2 status was 69 % and 74 %, respectively. Kaplan–Meier plots of PFS and OS by CTC-HER2 status revealed
significantly longer median [95 % CI] PFS of CTC-HER2-positive versus CTC-HER2-negative patients (7.4 [4.7–13.7] versus
4.34 [3.5–5.9] months; p = 0.035). CTC-HER2-positive status showed no significant difference for OS (13.7 [7.7–30.0] versus
8.7 [5.9–15.3] months; p = 0.287).
Conclusions: HER2 status can change during the course of breast cancer. CTC phenotyping may serve as an easy-to-perform
“liquid biopsy” to reevaluate HER2 status and potentially guide treatment decisions. Further, prospective studies are
needed.
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Metastatic breast cancer (MBC) is a heterogeneous dis-
ease. The current standard for predicting prognosis in
MBC is based on the primary tumor’s biological pheno-
type, the site of metastasis, and the line of therapy. As
MBC treatment evolves towards targeted therapy, the ef-
ficacy of novel therapies is also increasingly based on the
biological characteristics of the disease. However, these
are currently determined using primary tumor tissue
(e.g. HER2-status) or by means of sequential metastatic
tissue biopsies because breast cancer phenotype may
change during disease progression [1, 2]. This bears
several limitations: (1) Metastatic tissue may not be
available, (2) repeated sampling of metastatic tissue
may not be feasible due to increased morbidity, and (3)
metastatic breast cancer might be heterogeneous, im-
plying that tissue from a single metastasis obtained at a
single time point may not adequately reflect the tumor
burden.
Currently, markers to predict the efficacy of MBC
treatment frequently relate to the characteristics of the
primary tumor, even though antigen profiles of the pri-
mary tumor and the distant metastases have been re-
ported to differ in 7–20 % of patients [3–7]. Hence, a
reassessment of predictive markers, including the ex-
pression of human epidermal growth factor receptor 2
(HER2), might help to optimize MBC treatment [8, 9].
Due to the invasive nature of MBC, however, tissue sam-
pling of metastatic sites may be difficult to perform, es-
pecially if repeated sampling is required [10].
Tumor cell spread into the blood circulation plays a key
role during cancer progression. Currently, highly sensitive
methods are being developed to detect single circulating
tumor cells (CTCs), which are found in 40–80 % of
breast cancer patients with metastatic disease. Using the
CellSearch® technology cleared by the United States Food
and Drug Administration in 2004, large studies have
clearly demonstrated the adverse prognostic impact of
CTC counts ≥5 per 7.5 mL peripheral blood in patients
with MBC [11–17]. In addition, detection of CTCs in pri-
mary breast cancer has been shown to be an independent
prognostic marker for survival [18].
Apart from CTC enumeration to estimate prognosis,
CTC phenotype determination might be useful in pre-
dicting the efficacy of targeted therapy [8, 19–23]. Sam-
pling of metastatic tissue is associated with increased
morbidity, limiting the feasibility of repeated analysis.
Therefore, CTC characterization may offer an attractive
means of noninvasively monitoring the expression of
therapeutic targets in patients with breast cancer. In this
context, we conducted the present study to compare the
expression of HER2 in primary tumor tissue, metastatic
tissue, and CTCs. Moreover, we aimed to analyze the
impact of HER2 overexpression of CTCs on prognosis.Methods
Patients and study design
Patients treated for MBC at the National Center for
Tumor Diseases (NCT; Heidelberg, Germany) between
March 2010 and October 2013 were evaluated for this
exploratory study. CTC enumeration was performed be-
fore starting a new line of systemic treatment. Patients
with CTC counts ≥5 CTCs/7.5 mL peripheral blood
were defined as CTC-positive [11]. Only CTC-positive
patients were included in this analysis. Additional cri-
teria for inclusion were age >18 years, clinical and radio-
logical evidence of measurable or evaluable metastatic
disease according to the Response Evaluation Criteria in
Solid Tumors (RECIST) criteria [24], progressive meta-
static disease, and written informed consent for study par-
ticipation, data collection and analysis, and publication.
Patient records were reviewed for reports of metastatic tis-
sue biopsies. Patients with malignancies other than breast
cancer were excluded. Ethical approval was obtained
from the Ethics Committee of the Medical Faculty of the
University of Heidelberg.Enumeration and HER2 characterization of CTCs
Enrichment and enumeration of CTCs using the CellSearch
technology (CellSearch™ Epithelial Cell Kit/CellSpotter™
Analyzer, Janssen Diagnostics LLC, Raritan, NJ, USA) was
essentially performed as described elsewhere [25]. Briefly,
7.5 mL samples of peripheral whole blood were collected in
CellSave tubes (Janssen Diagnostics LLC, Raritan, NJ, USA)
containing ethylenediaminetetraacetic acid (EDTA) and a
cellular preservative. Samples were maintained at room
temperature and processed within 96 h. Epithelial cells
were immunomagnetically enriched using ferrofluid nano-
particles coated with antibodies against epithelial cell adhe-
sion molecule (EpCAM). Subsequently, EpCAM-positive
cells were labeled with the nuclear dye 4′,6-diamidino-2-
phenylindole (DAPI) and immunostained with monoclonal
antibodies specific for keratins and for the leukocyte com-
mon antigen CD45. Cells with intact nuclei that were
CD45-negative and keratin-positive were defined as CTCs
and enumerated by trained operators. Blood samples con-
taining ≥5 CTCs/7.5 mL blood were considered CTC-
positive, as published previously [11].
HER2 expression on CTCs was characterized within
the CellSearch technology using an anti-HER2 antibody
labeled with fluorescein isothiocyanate (FITC, CellSearch
tumor phenotyping reagent HER2, Janssen Diagnostics
LLC, Raritan, NJ, USA), as described previously [19, 26,
27]. The intensity of HER2-specific immunofluorescence
was scored as negative (0), weak (1+), moderate (2+), or
strong (3+). CTC status was considered HER2-positive
(CTC-HER2-positive) if at least one CTC exhibited
strong (3+) or moderate (2+) HER2 staining [8].
Table 1 Patient characteristics and CTC-HER status
Total CTC-HER2-positive p-value
Total, n (%) 107 37 (35)
Age at primary diagnosis,
years; median (range)
49 (33–81) 49 (35–77) 0.594
Age at enrollment, years;
median (range)
57 (33–81) 58 (40–77) 0.517
ER status, n (%) 0.253
Negative 78 30 (38)
Positive 29 7 (24)
PR status, n (%) 0.673
Negative 68 25 (37)
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The HER2 status was determined for the primary tumor
(PRIM-HER2 status) and metastatic tissue (MET-HER2
status) using the immunohistochemistry-based HERCEP™
test (DAKO, Glostrup, Denmark) for semi-quantitative
detection of HER2 expression in breast cancer tissue. Ex-
pression of HER2 was scored on a scale from 0 to 3+. Pri-
mary tumor and metastatic tissue samples with a score of
3+ were considered PRIM-HER2-positive and MET-
HER2-positive, respectively. In cases where the score was
2+, HER2 amplification was determined by fluorescence
in-situ hybridization (FISH) using the Pathvysion Kit
(Vysis Inc., Downers Grove, IL, USA).Positive 39 12 (31)
Number of metastatic
sites, n (%)
0.799
One site 21 8 (38)
Multiple sites 86 29 (34)
Site of metastasis, n (%) 0.626
Bone 19 5 (26)
Visceral 22 7 (32)
Both 66 25 (38)
Line of therapy, n (%)a 0.268
First 51 18 (35)
Second 22 10 (45)
Further 33 8 (24)
ER estrogen receptor, PR progesterone receptor
aLine of therapy unknown for one patientData collection and analysis
All data were extracted systematically from treatment re-
cords. Demographic data and clinical characteristics
were described as frequency and percentage, median and
range, or mean and standard deviation. Groups were
compared using the Wilcoxon rank test or Fisher’s exact
test, as appropriate. Kaplan–Meier plots by CTC-HER2
status were generated with R, version 3.0.0 [28], for PFS
and OS (time from initiation of the new line of systemic
treatment to disease progression and death from any
cause, respectively), with data being censored at last
follow-up if progression or death had not occurred. PFS
and OS times were estimated as medians with 95 % con-
fidence intervals (CIs). Differences in PFS and OS by
CTC-HER2 status were assessed by the log-rank test. All
statistical tests were done using R, version 3.0.0 with
package survival [28]. A significance level of 5 % was
chosen.Results
Patient characteristics
In total, 107 CTC-positive patients with a median age of
57 years (range, 33–81) were included in the analysis.
100/107 (93 %) patients were followed-up for a median
[95 % CI] of 28.5 [25.1–40.1] months. Table 1 details the
patient characteristics. Figure 1 shows the flow of pa-
tients through the study and indicates the number of pa-
tients with metastatic tumor tissue. The primary tumor
was estrogen receptor (ER)-positive in 78 (73 %) pa-
tients, progesterone receptor (PR)-positive in 68 (64 %)
patients, and HER2-negative in 91 (85 %) patients. 80 %
of all patients had multiple metastatic sites, 18 % had
bone metastases, 21 % had visceral or local metastases,
and 62 % had both. 48 % of all patients received first-
line treatment for MBC, 21 % second-line treatment,
and 31 % third- or further-line treatment (line unknown
in one patient). 13 % of patients were pretreated with
HER2-targeted therapy before study entry. The median
time from biopsy of the primary tumor to biopsy ofmetastatic lesions was 44 months. The median time
from biopsy of metastases to CTC analysis was 230 days.HER2 status of CTCs, primary tumor, and metastases
The median number (range) of CTCs detected per
7.5 mL blood was 27 (5–5000). HER2-positive CTCs
were detected in 37/107 (35 %) patients. There was no
significant association between CTC-HER2 status and
CTC count or any other factor shown in Table 1.
As shown in Table 2, only 10 (27 %) of the 37 CTC-
HER2-positive patients had a HER2-positive primary
tumor (PRIM). The overall accuracy between CTC-HER2
and PRIM-HER2 status was 69 %. The HER2 status of
metastatic tissue samples (MET) was available for 46 pa-
tients, of whom 6 (13 %) were MET-HER2-positive.
HER2-positive metastasis was observed only in 2 out of 10
(20 %) CTC-HER2-positive patients. The overall accuracy
between CTC-HER2 and MET-HER2 status was 74 %. As
shown in Table 3, the overall accuracy between PRIM-
HER2 and MET-HER2 status was 38/46 (83 %). 3/46 (7 %)
breast cancers were PRIM-HER2-positive and MET-
HER2-negative, whereas 5/46 (11 %) were PRIM-HER2-
negative and MET-HER2-positive.
Fig. 1 Patient flow through the study
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Follow-up data were available for 100/107 (93 %) pa-
tients with a median follow-up period [95 % CI] of 28.5
[25.1–40.1] months. Figure 2 shows the Kaplan–Meier
plots of PFS and OS by CTC-HER2 status. PFS was sig-
nificantly longer in CTC-HER2-positive patients than in
CTC-HER2-negative patients (p = 0.035), the respective
median PFS times [95 % CI] being 7.4 [4.7–13.7] and 4.3
[3.5–5.9] months. In contrast, the association of CTC-
HER2-positive status with a longer OS of 13.7 [7.7–30.0]
months as compared with 8.7 [5.9–15.3] months for
CTC-HER2-negative status was not statistically signifi-
cant (p = 0.287).
Discussion
Although the expression of therapeutic targets may
change during the course of disease, treatment decisions
for MBC are often based on primary tumor characteris-
tics [29]. Therefore, current treatment guidelines recom-
mend reevaluation of patients with MBC for the HER2Table 2 Comparison of CTCs, primary tumor, and metastatic tissue
by HER2 status in patients with MBC
Total CTC-HER2-negative CTC-HER2-positive
n (%) n (%)
PRIM-HER2 status (total) 107 70 (65 %) 37 (35 %)
Negative 91 64 (70 %) 27 (30 %)
Positive 16 6 (38 %) 10 (62 %)
MET-HER2 status (total) 46 36 (78 %) 10 (22 %)
Negative 40 32 (80 %) 8 (20 %)
Positive 6 4 (67 %) 2 (33 %)
Overall accuracy of CTC-HER2 and PRIM-HER2 status: 69 %; overall accuracy of
CTC-HER2 and MET-HER2 status: 74 %and hormone receptor status of metastatic tissue
(www.ago-online.de). However, this is an invasive pro-
cedure that could be difficult to perform, especially if
sampling needs to be repeated [10]. By contrast, CTCs
provide a very promising, easy to repeat, real-time “li-
quid biopsy” approach. CTCs offer the advantage that
the therapeutic targets they express may more accurately
represent the currently most important subpopulation of
tumor cells thus potentially making CTCs better predic-
tors of the efficacy of targeted treatments [30].
Our results confirm that HER2 expression in meta-
static tissue does not necessarily reflect the phenotype of
the primary tumor. The process of tumor progression
and distant metastasis is highly selective, involves gen-
etic changes that also affect HER2 status, and mainly, is
accompanied by selection of HER2-positive or HER2-
negative cells. The 83 % overall accuracy in HER2 status
we found between metastatic tissue and primary tumor
is in line with other studies, which report overall accuracy
rates of 70–95 % [3–6]. About 10 % of patients with ini-
tially HER2-negative disease presented with HER2-
positive metastasis and therefore were potentially exposed
to undertreatment in the absence of HER2-directed ther-
apy. Moreover, the HER2 status of a single metastatic bi-
opsy sample might not accurately enough reflect theTable 3 Comparison of primary tumor and metastatic tissue by
HER2 status (PRIM-HER2 and MET-HER2 status, respectively)
Total MET-HER2-negative MET-HER2-positive
PRIM-HER2
status (total)
46 (100 %) 40/46 (87 %) 6/46 (13 %)
Negative 42/46 (91 %) 37/42 (88 %) 5/42 (12 %)
Positive 4/46 (9 %) 3/4 (7 %) 1/4 (25 %)
Overall accuracy of MET-HER2 and PRIM-HER2 status: 83 %
Fig. 2 Kaplan–Meier plots of progression-free survival (a) and overall survival (b) of CTC-positive (≥5 CTCs/7.5 mL blood) MBC patients by CTC-HER2 status
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sampling from a single metastasis, the detection and enu-
meration of CTCs represents an attractive, noninvasive al-
ternative that also enables repeated evaluation of the
phenotype of the currently circulating, i.e. probably most
active, tumor cells [9]. We found a 74 % overall accuracy
in HER2 status between metastatic tissue and CTCs.
However, this comparison is limited by the fact that the
biopsies of metastatic tissue and blood sampling for CTC
studies were not performed simultaneously. Ideally, the
CTC-HER2 and MET-HER2 assessments should be per-
formed in temporal proximity because CTC status is
known to be dynamic and therefore the time between the
two determinations may be relevant. However, in routine
clinical practice the time lapse can be considerable. More-
over, HER2-targeted treatment of PRIM-HER2-positive
patients before biopsy of metastatic tissue or CTC sam-
pling may interfere with HER2 testing. In our present
study, metastatic tissue was available only from 10 CTC-
HER2-positive patients, and therefore our findings regard-
ing the incidence of HER2-positive metastasis in CTC-
HER2-positive patients should be interpreted with caution.
Clarification of these aspects requires prospective studies
such as the German DETECT study (NCT01619111). This
is a phase III multicenter trial in which patients with a
HER2-negative primary tumor but HER2-positive CTCs
are randomized to standard treatment alone or in combin-
ation with the dual HER1/HER2 tyrosine kinase inhibitor
lapatinib.
To determine the HER2 status of CTCs, we used an im-
munofluorescence staining score previously established by
Meng et al. [19] and Riethdorf et al. [27]. These authors
demonstrated a high overall accuracy between immuno-
fluorescence and FISH analysis of single cells. The present
study defined a patient as CTC-HER2-positive if she was
CTC-positive with ≥5 CTCs/7.5 mL blood and had at least
one CTC with an immunostaining score of 3+ or 2+. This
definition was proposed by Fehm et al., who recentlypresented a prospective multicenter trial investigating
HER2 expression on CTCs in patients with MBC [8]. In
line with their study, one-third of our patients had at least
one CTC with strong or moderate, i.e. 3+ or 2+, overex-
pression of HER2, and 31 % of patients had a CTC-HER2
status different from their primary tumor’s HER2 status.
Hence, it is possible that 10 % of all patients with MBC
might benefit from HER2-directed treatment despite their
primary tumor being HER2-negative since about 80 % of
all patients are PRIM-HER2-negative, half of whom are
CTC-positive (≥5 CTCs/7.5 mL blood) in the metastatic
setting where the rate of CTC-HER2 positivity (i.e., immu-
nostaining score 3+ or 2+) is about 30 %.
However, there are also other definitions of CTC-
HER2 positivity. For instance, Pestrin et al. and Meng
et al. defined a patient as CTC-HER2-positive if the re-
ceptor was strongly overexpressed on at least 50 % of
CTCs [19, 20]. On the other hand, studying primary
breast cancer, where the CTC detection rate is lower than
in MBC, Riethdorf et al. also used the presence of at least
one HER2-positive CTC as a cut-off level [27]. To estab-
lish a robust predictive marker, an optimal cut-off level for
CTC-HER2 positivity needs to be defined in prospective
trials. An even more restrictive definition of CTC-HER2
positivity (only CTCs with 3+ staining) than the one we
used in the present study (3+ or 2+ staining) is currently
being evaluated in the above-mentioned DETECT study.
Interestingly, we found that patients with HER2-positive
CTCs had had a significantly longer PFS than patients
who were CTC-HER2-negative. This is in contrast to
other studies that evaluated the impact of HER2-positive
CTCs on survival [21, 31]. However, these studies com-
pared the prognosis of CTC-HER2-positive patients with
the prognosis of patients without CTCs. By contrast, all
patients in our study were CTC-positive, which per se is
associated with an extremely poor prognosis. However, in
view of the relatively small number of patients and the
lack of significant impact of CTC-HER2 status on OS, our
Wallwiener et al. BMC Cancer  (2015) 15:403 Page 6 of 7results should be interpreted with caution. Moreover,
these results are likely to be biased by HER-targeted treat-
ment as 11 of the 37 CTC-HER2-positive patients had a
HER2-positive primary tumor or HER2-positve metasta-
sis, or both.
Limitations of the study
Potential limitations of the study include its retrospective
design, the lack of FISH diagnostics for all HER2 assess-
ments, the variability of HER2 immunohistochemistry
testing, and the fact that the sample size was too small for
multivariate analysis.
Conclusions
Our findings confirm that the HER2 status of breast can-
cer may change during the course of disease, with import-
ant consequences for the efficacy of targeted treatment. In
this context, CTC phenotyping may serve as a “liquid bi-
opsy” that is easily performed and repeated during breast
cancer treatment and is a promising aid in guiding treat-
ment decisions. The clinical value of CTCs in predicting
the efficacy of HER2-directed therapy is currently being
investigated in prospective randomized trials.
Abbreviations
CI: Confidence interval; CTC: Circulating tumor cell; CTC-HER2 status: HER2
status of CTCs; DAPI: 4′,6-diamidino-2-phenylindole;
EDTA: Ethylenediaminetetraacetic acid; EpCAM: Epithelial cell adhesion
molecule; ER: Estrogen receptor; FISH: Fluorescence in situ hybridization;
FITC: Fluorescein isothiocyanate; HER2: Human epidermal growth factor
receptor 2; MET-HER2 status: HER2 status of metastatic tissue; NCT: National
Center for Tumor Diseases, Heidelberg, Germany; PR: Progesterone receptor;
PRIM-HER2 status: HER2 status of primary tumor; RECIST: Response Evaluation
Criteria in Solid Tumors.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
MW, ADH, KP, AT, and AS jointly conceived the study and developed its
design. MW and AS supervised the study. SR and KP developed the
methodology. MW, ADH, SR, JN, MRS, FAT, JH, CS, KP, AT, and AS participated
in patient recruitment, patient management, clinical data collection, sample
collection, and sample analysis. BS and JN organized and reported the data,
constructed the databases, and conducted data management. BS performed
the statistical analysis. MW, ADH, SR, MRS, BS, FAT, JH, CS, AT, and AS
participated in data analysis and interpretation. MW, ADH, BS, and AS drafted
the manuscript. SR, JN, MRS, FAT, JH, CS, KP, and AT revised the draft
manuscript for important intellectual input. MW, ADH, BS, and AS prepared
the final manuscript. All authors read and approved the final manuscript.
Authors’ information
MW and ADH are joint first authors.
Acknowledgements
The authors gratefully acknowledge all patients whose data were used in
this study. We also thank the medical and nursing staff, especially Martina
Scharpff, at the National Center for Tumor Diseases (NCT; Heidelberg) for the
excellent management and care of our patients, the NCT laboratory staff
who did the CTC and MET-HER2 determinations, and Antje Andreas, Cornelia
Coith and Oliver Mauermann (Hamburg), who provided excellent technical
assistance with the CTC-HER2 determinations.
This study was supported by NCT in-house funds, made available to AS and
AT, and by grants to AT from the BioRN Leading Edge Cluster “Molecularand Cell Based Medicine” (BRN 02GS1893), supported by the German Federal
Ministry of Education and Research (BMBF), Berlin, Germany (BMBF N02/74829)
and the Dietmar Hopp Foundation. We acknowledge financial support from the
German Research Foundation (DFG) and Ruprecht-Karls-Universität Heidelberg
through the funding program for Open Access Publishing.
Author details
1Department of Obstetrics and Gynecology, University of Heidelberg, Im
Neuenheimer Feld 440, 69120 Heidelberg, Germany. 2Department of
Obstetrics and Gynecology, University of Tübingen, Calwerstraße 7, 72076
Tübingen, Germany. 3Department of Tumor Biology, University Medical
Center Hamburg-Eppendorf, Martinistraße 52, 20246 Hamburg, Germany.
4National Center for Tumor Diseases, Im Neuenheimer Feld 460, 69120
Heidelberg, Germany. 5Heidelberg Institute for Stem Cell Technology and
Experimental Medicine (HI-STEM gGmbH), Im Neuenheimer Feld 280, 69120
Heidelberg, Germany. 6Division of Stem Cells and Cancer, German Cancer
Research Center (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg,
Germany.
Received: 5 December 2014 Accepted: 6 May 2015References
1. Loehberg CR, Almstedt K, Jud SM, Haeberle L, Fasching PA, Hack CC, et al.
Prognostic relevance of Ki-67 in the primary tumor for survival after a diagnosis
of distant metastasis. Breast Cancer Res Treat. 2013;138:899–908.
2. Hartkopf A, Brendel M, Wallwiener M, Taran FA, Brucker S, Grischke EM.
Trastuzumab administration in patients with metastatic breast cancer – experience
of a large University Breast Center. Geburtshilfe Frauenheilkd. 2014;74:563–8.
3. Tanner M, Jarvinen P, Isola J. Amplification of HER-2/neu and topoisomerase
IIalpha in primary and metastatic breast cancer. Cancer Res.
2001;61:5345–8.
4. Gancberg D, Di Leo A, Cardoso F, Rouas G, Pedrocchi M, Paesmans M, et al.
Comparison of HER-2 status between primary breast cancer and corresponding
distant metastatic sites. Ann Oncol. 2002;13:1036–43.
5. Edgerton SM, Moore 2nd D, Merkel D. Thor AD: erbB-2 (HER-2) and breast
cancer progression. Appl Immunohistochem Mol Morphol. 2003;11:214–21.
6. Santinelli A, Pisa E, Stramazzotti D, Fabris G. HER-2 status discrepancy between
primary breast cancer and metastatic sites. Impact on target therapy. Int J
Cancer. 2008;122:999–1004.
7. Hartkopf AD, Banys M, Meier-Stiegen F, Hahn M, Rohm C, Hoffmann J, et al.
The HER2 status of disseminated tumor cells in the bone marrow of early
breast cancer patients is independent from primary tumor and predicts
higher risk of relapse. Breast Cancer Res Treat. 2013;138:509–17.
8. Fehm T, Müller V, Aktas B, Janni W, Schneeweiss A, Stickeler E, et al. HER2
status of circulating tumor cells in patients with metastatic breast cancer: a
prospective, multicenter trial. Breast Cancer Res Treat. 2010;124:403–12.
9. Hartkopf AD, Banys M, Fehm T. HER2-positive DTCs/CTCs in breast cancer.
Recent Results Cancer Res. 2012;195:203–15.
10. Banys M, Hartkopf AD, Krawczyk N, Becker S, Fehm T. Clinical implications of
the detection of circulating tumor cells in breast cancer patients. Biomark
Med. 2012;6:109–18.
11. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, et al. Circulating
tumor cells, disease progression, and survival in metastatic breast cancer. N Engl
J Med. 2004;351:781–91.
12. Liu MC, Shields PG, Warren RD, Cohen P, Wilkinson M, Ottaviano YL, et al.
Circulating tumor cells: a useful predictor of treatment efficacy in metastatic
breast cancer. J Clin Oncol. 2009;27:5153–9.
13. Giuliano M, Giordano A, Jackson S, Hess KR, De Giorgi U, Mego M, et al.
Circulating tumor cells as prognostic and predictive markers in metastatic
breast cancer patients receiving first-line systemic treatment. Breast Cancer
Res. 2011;13:R67.
14. Giordano A, Giuliano M, De Laurentiis M, Arpino G, Jackson S, Handy BC, et al.
Circulating tumor cells in immunohistochemical subtypes of metastatic breast
cancer: lack of prediction in HER2-positive disease treated with targeted therapy.
Ann Oncol. 2012;23:1144–50.
15. Pierga JY, Hajage D, Bachelot T, Delaloge S, Brain E, Campone M, et al. High
independent prognostic and predictive value of circulating tumor cells compared
with serum tumor markers in a large prospective trial in first-line chemotherapy for
metastatic breast cancer patients. Ann Oncol. 2012;23:618–24.
Wallwiener et al. BMC Cancer  (2015) 15:403 Page 7 of 716. Wallwiener M, Hartkopf AD, Baccelli I, Riethdorf S, Schott S, Pantel K, et al.
The prognostic impact of circulating tumor cells in subtypes of metastatic
breast cancer. Breast Cancer Res Treat. 2013;137:503–10.
17. Bidard FC, Peeters DJ, Fehm T, Nole F, Gisbert-Criado R, Mavroudis D, et al.
Clinical validity of circulating tumour cells in patients with metastatic breast
cancer: a pooled analysis of individual patient data. Lancet Oncol. 2014;406–414.
18. Rack B, Schindlbeck C, Juckstock J, Andergassen U, Hepp P, Zwingers T, et al.
Circulating tumor cells predict survival in early average-to-high risk breast
cancer patients. J Natl Cancer Inst. 2014;106.
19. Meng S, Tripathy D, Shete S, Ashfaq R, Haley B, Perkins S, et al. HER-2 gene
amplification can be acquired as breast cancer progresses. Proc Natl Acad
Sci U S A. 2004;101:9393–8.
20. Pestrin M, Bessi S, Galardi F, Truglia M, Biggeri A, Biagioni C, et al. Correlation of
HER2 status between primary tumors and corresponding circulating tumor cells
in advanced breast cancer patients. Breast Cancer Res Treat. 2009;118:523–30.
21. Munzone E, Nole F, Goldhirsch A, Botteri E, Esposito A, Zorzino L, et al.
Changes of HER2 status in circulating tumor cells compared with the
primary tumor during treatment for advanced breast cancer. Clin Breast
Cancer. 2010;10:392–7.
22. Ignatiadis M, Rothe F, Chaboteaux C, Durbecq V, Rouas G, Criscitiello C,
et al. HER2-positive circulating tumor cells in breast cancer. PLoS One.
2011;6, e15624.
23. Nadal R, Fernandez A, Sanchez-Rovira P, Salido M, Rodriguez M, Garcia-Puche
JL, et al. Biomarkers characterization of circulating tumour cells in breast cancer
patients. Breast Cancer Res. 2012;14:R71.
24. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al.
New response evaluation criteria in solid tumours: revised RECIST guideline
(version 1.1). Eur J Cancer. 2009;45:228–47.
25. Riethdorf S, Fritsche H, Muller V, Rau T, Schindlbeck C, Rack B, et al. Detection
of circulating tumor cells in peripheral blood of patients with metastatic breast
cancer: a validation study of the cell search system. Clin Cancer Res.
2007;13:920–8.
26. Hayes DF, Walker TM, Singh B, Vitetta ES, Uhr JW, Gross S, et al. Monitoring
expression of HER-2 on circulating epithelial cells in patients with advanced
breast cancer. Int J Oncol. 2002;21:1111–7.
27. Riethdorf S, Müller V, Zhang L, Rau T, Loibl S, Komor M, et al. Detection and
HER2 expression of circulating tumor cells: prospective monitoring in breast
cancer patients treated in the neoadjuvant GeparQuattro trial. Clin Cancer
Res. 2010;16:2634–45.
28. R: A Language and Environment for Statistical Computing www.r-project.org.
29. Sinn P, Aulmann S, Wirtz R, Schott S, Marmé F, Varga Z, et al. Multigene
assays for classification, prognosis, and prediction in breast cancer: a critical
review on the background and clinical utility. Geburtshilfe Frauenheilkd.
2013;73:932–40.
30. Pantel K, Alix-Panabieres C. Real-time liquid biopsy in cancer patients: fact or
fiction? Cancer Res. 2013;73:6384–8.
31. Wulfing P, Borchard J, Buerger H, Heidl S, Zanker KS, Kiesel L, et al. HER2-positive
circulating tumor cells indicate poor clinical outcome in stage I to III breast
cancer patients. Clin Cancer Res. 2006;12:1715–20.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
